NZ722326A - Tricyclic compounds as anticancer agents - Google Patents
Tricyclic compounds as anticancer agentsInfo
- Publication number
- NZ722326A NZ722326A NZ72232614A NZ72232614A NZ722326A NZ 722326 A NZ722326 A NZ 722326A NZ 72232614 A NZ72232614 A NZ 72232614A NZ 72232614 A NZ72232614 A NZ 72232614A NZ 722326 A NZ722326 A NZ 722326A
- Authority
- NZ
- New Zealand
- Prior art keywords
- tricyclic compounds
- anticancer agents
- compounds
- compositions
- tricyclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361920500P | 2013-12-24 | 2013-12-24 | |
| PCT/US2014/072031 WO2015100282A1 (en) | 2013-12-24 | 2014-12-23 | Tricyclic compounds as anticancer agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ722326A true NZ722326A (en) | 2019-09-27 |
Family
ID=52293305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ72232614A NZ722326A (en) | 2013-12-24 | 2014-12-23 | Tricyclic compounds as anticancer agents |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US20160318928A1 (OSRAM) |
| EP (2) | EP3087071B1 (OSRAM) |
| JP (2) | JP6466456B2 (OSRAM) |
| KR (1) | KR102457145B1 (OSRAM) |
| CN (2) | CN108558871B (OSRAM) |
| AR (2) | AR099379A1 (OSRAM) |
| AU (1) | AU2014369982B2 (OSRAM) |
| BR (1) | BR112016013744B1 (OSRAM) |
| CA (1) | CA2934953C (OSRAM) |
| CL (1) | CL2016001629A1 (OSRAM) |
| CY (2) | CY1121076T1 (OSRAM) |
| DK (2) | DK3466949T3 (OSRAM) |
| EA (2) | EA201990240A1 (OSRAM) |
| ES (2) | ES2698998T3 (OSRAM) |
| HR (2) | HRP20181849T1 (OSRAM) |
| HU (2) | HUE054183T2 (OSRAM) |
| IL (1) | IL246359B (OSRAM) |
| LT (2) | LT3087071T (OSRAM) |
| MA (1) | MA39211B1 (OSRAM) |
| MX (1) | MX369491B (OSRAM) |
| MY (1) | MY176489A (OSRAM) |
| NZ (1) | NZ722326A (OSRAM) |
| PE (1) | PE20160844A1 (OSRAM) |
| PH (1) | PH12016500953A1 (OSRAM) |
| PL (2) | PL3466949T3 (OSRAM) |
| PT (2) | PT3466949T (OSRAM) |
| RS (2) | RS61479B1 (OSRAM) |
| SG (1) | SG11201605097SA (OSRAM) |
| SI (2) | SI3466949T1 (OSRAM) |
| SM (2) | SMT201800643T1 (OSRAM) |
| TN (1) | TN2016000238A1 (OSRAM) |
| TW (2) | TWI736517B (OSRAM) |
| UY (1) | UY35916A (OSRAM) |
| WO (1) | WO2015100282A1 (OSRAM) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014134267A1 (en) | 2013-02-27 | 2014-09-04 | Bristol-Myers Squibb Company | Carbazole compounds useful as bromodomain inhibitors |
| WO2015070020A2 (en) | 2013-11-08 | 2015-05-14 | Dana-Farber Cancer Institute, Inc. | Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors |
| PL3466949T3 (pl) * | 2013-12-24 | 2021-05-31 | Bristol-Myers Squibb Company | Związek tricykliczny jako środki przeciwrakowe |
| US9458156B2 (en) | 2014-12-23 | 2016-10-04 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
| US9580430B2 (en) * | 2014-02-28 | 2017-02-28 | The Regents Of The University Of Michigan | 9H-pyrimido[4,5-B]indoles and related analogs as BET bromodomain inhibitors |
| WO2016183115A1 (en) * | 2015-05-12 | 2016-11-17 | Bristol-Myers Squibb Company | 5h-pyrido[3,2-b]indole compounds as anticancer agents |
| US9725449B2 (en) | 2015-05-12 | 2017-08-08 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
| JP7032311B2 (ja) | 2015-07-16 | 2022-03-08 | バイオエクセル セラピューティクス，インコーポレイテッド | 免疫調節を使用してがんを処置するための新規手法 |
| EP3355922A2 (en) * | 2015-10-02 | 2018-08-08 | Dana Farber Cancer Institute, Inc. | Combination therapy of bromodomain inhibitors and checkpoint blockade |
| KR102238012B1 (ko) * | 2016-01-20 | 2021-04-09 | 닝보 웬다 파르마 테크놀로지 엘티디 | 브로모도메인 억제제인 카르볼린 유도체 |
| WO2017124934A1 (zh) * | 2016-01-20 | 2017-07-27 | 宁波文达医药科技有限公司 | 作为布罗莫区结构域抑制剂的含膦咔啉衍生物 |
| EP3412669A4 (en) * | 2016-02-05 | 2019-09-04 | Chia Tai Tianqing Pharmaceutical Group Co.,Ltd | TRICYCLIC COMPOUND FOR PROTEIN INHIBITOR CONTAINING BROMODOMAINE AND PREPARATION, PHARMACEUTICAL COMPOSITION AND USE THEREOF |
| IL297201A (en) | 2016-03-01 | 2022-12-01 | Corcept Therapeutics Inc | Use of glucocorticoid receptor modulators to increase the activity of checkpoint inhibitors |
| US10150754B2 (en) * | 2016-04-19 | 2018-12-11 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| US20190284192A1 (en) | 2016-11-10 | 2019-09-19 | Luoxin Pharmaceutical (Shanghai) Co., Ltd. | Nitrogenous macrocyclic compound, preparation method therefor, pharmaceutical composition and application thereof |
| CN109824693B (zh) * | 2017-04-18 | 2020-12-08 | 四川大学 | Brd4抑制剂及其在肿瘤治疗药物中的应用 |
| WO2019080941A1 (en) * | 2017-10-27 | 2019-05-02 | Jacobio-Beta Pharmaceuticals Co., Ltd. | NEW TRICYCLIC COMPOUNDS |
| KR102600391B1 (ko) | 2018-06-25 | 2023-11-10 | 자코바이오 파마슈티칼스 컴퍼니 리미티드 | 삼중고리형 화합물 |
| CN108840868B (zh) * | 2018-08-01 | 2019-10-18 | 上海山的实业有限公司 | 具有抗肿瘤活性的吲哚并吡啶酮类化合物的制备方法及应用 |
| US11389432B2 (en) | 2018-12-19 | 2022-07-19 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| US11234971B2 (en) | 2018-12-19 | 2022-02-01 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| WO2020200284A1 (zh) * | 2019-04-04 | 2020-10-08 | 上海华汇拓医药科技有限公司 | 三环类化合物制备方法及其在医药领域的应用 |
| CN110003204B (zh) * | 2019-04-30 | 2020-08-11 | 上海勋和医药科技有限公司 | 一种bet蛋白抑制剂、其制备方法及用途 |
| US10947253B2 (en) | 2019-08-05 | 2021-03-16 | Ankh Life Sciences Limited | Fused polycyclic dimers |
| JP7642552B2 (ja) | 2019-09-30 | 2025-03-10 | 協和キリン株式会社 | Ｂｅｔ分解剤 |
| US12129265B2 (en) | 2020-07-21 | 2024-10-29 | Ankh Life Sciences Limited | Therapeutic agents and uses thereof |
| AU2022211285A1 (en) * | 2021-01-22 | 2023-08-17 | Jingrui Biopharma Co., Ltd. | Tricyclic compounds as anticancer agents |
| CA3206708A1 (en) * | 2021-02-25 | 2022-09-01 | Ida ARONCHIK | Use of a bet inhibitor alone or in combination with fedratinib or ruxolitinib for treating a hematological malignancy such as myelofibrosis |
| WO2022234337A2 (en) * | 2021-05-06 | 2022-11-10 | Raziel Therapeutics Ltd. | Crystalline carbazole derivative |
| WO2024099441A1 (en) * | 2022-11-11 | 2024-05-16 | Jingrui Biopharma (Shandong) Co., Ltd. | Bromodomain and extra-terminal (bet) protein degrader |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0623125A1 (en) * | 1992-01-15 | 1994-11-09 | E.I. Du Pont De Nemours And Company | Bridged heterocyclic fungicides |
| JP2007509045A (ja) | 2003-10-18 | 2007-04-12 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | 尿失禁および関連疾患の処置用のｇａｂａアゴニストとしての５−置換２−（フェニルメチル）チオ−４−フェニル−４ｈ−１，２，４−トリアゾール誘導体および関連化合物 |
| EP1686949A2 (en) * | 2003-11-24 | 2006-08-09 | Viropharma Incorporated | Compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| DK1866339T3 (da) | 2005-03-25 | 2013-09-02 | Gitr Inc | GTR-bindende molekyler og anvendelser heraf |
| GB0507298D0 (en) | 2005-04-11 | 2005-05-18 | Novartis Ag | Organic compounds |
| WO2006122150A1 (en) | 2005-05-10 | 2006-11-16 | Incyte Corporation | Modulators of indoleamine 2,3-dioxygenase and methods of using the same |
| RS54271B1 (sr) | 2005-07-01 | 2016-02-29 | E. R. Squibb & Sons, L.L.C. | Humana monoklonska antitela za ligand programirane smrti 1 (pd-l1) |
| JP5294874B2 (ja) | 2005-12-20 | 2013-09-18 | インサイト・コーポレイション | インドールアミン２，３−ジオキシゲナーゼのモジュレーターとしてのｎ−ヒドロキシアミジノヘテロ環 |
| US7696166B2 (en) | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| JP5319532B2 (ja) | 2006-09-19 | 2013-10-16 | インサイト・コーポレイション | インドールアミン２，３−ジオキシゲナーゼのモジュレーターとしてのｎ−ヒドロキシアミジノヘテロサイクル |
| UY30892A1 (es) | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| ES2776406T3 (es) | 2007-07-12 | 2020-07-30 | Gitr Inc | Terapias de combinación que emplean moléculas de enlazamiento a GITR |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| CA2932121A1 (en) | 2007-11-30 | 2009-06-11 | Newlink Genetics Corporation | Ido inhibitors |
| FR2927330B1 (fr) | 2008-02-07 | 2010-02-19 | Sanofi Aventis | Derives de 5,6-bisaryl-2-pyridine-carboxamide, leur preparation et leur application en therapeutique comme antagonistes des recepteurs a l'urotensine ii |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| HRP20170908T1 (hr) | 2008-12-09 | 2017-09-22 | F. Hoffmann - La Roche Ag | Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice |
| US8815840B2 (en) * | 2008-12-19 | 2014-08-26 | Bristol-Myers Squibb Company | Carbazole and carboline kinase inhibitors |
| US8709424B2 (en) | 2009-09-03 | 2014-04-29 | Merck Sharp & Dohme Corp. | Anti-GITR antibodies |
| ES2601226T3 (es) | 2009-10-28 | 2017-02-14 | Newlink Genetics Corporation | Derivados de imidazol como inhibidores de IDO |
| RS58693B1 (sr) | 2009-12-10 | 2019-06-28 | Hoffmann La Roche | Antitela koja poželjno vezuju ekstracelularni domen 4 humanog csf1r, i njihova primena |
| TW201141872A (en) | 2010-02-26 | 2011-12-01 | Boehringer Ingelheim Int | Cycloalkyl containing thienopyrimidines for pharmaceutical compositions |
| PH12018501083A1 (en) | 2010-03-04 | 2019-02-18 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| BR112012020372A8 (pt) | 2010-03-05 | 2018-01-02 | Hoffmann La Roche | anticorpo que se liga ao csf-1r humano, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira e método para a produção de um anticorpo recombinante |
| CA2789071C (en) | 2010-03-05 | 2018-03-27 | F. Hoffmann-La Roche Ag | Antibodies against human csf-1r and uses thereof |
| TWI503323B (zh) * | 2010-03-29 | 2015-10-11 | Oncotherapy Science Inc | 三環化合物以及含此化合物之ｐｂｋ抑制劑 |
| KR20200044999A (ko) | 2010-05-04 | 2020-04-29 | 파이브 프라임 테라퓨틱스, 인크. | Ｃｓｆ1ｒ에 결합하는 항체들 |
| EP2582698B1 (en) | 2010-06-16 | 2016-09-14 | Vitae Pharmaceuticals, Inc. | Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use |
| PH12020550156A1 (en) | 2010-09-09 | 2024-01-15 | Pfizer | 4-1bb binding molecules |
| KR20140099556A (ko) * | 2010-12-16 | 2014-08-12 | 에프. 호프만-라 로슈 아게 | 트라이사이클릭 pi3k 억제제 화합물 및 이의 사용 방법 |
| US8580399B2 (en) | 2011-04-08 | 2013-11-12 | Universal Display Corporation | Substituted oligoazacarbazoles for light emitting diodes |
| NO2694640T3 (OSRAM) | 2011-04-15 | 2018-03-17 | ||
| CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| US9991447B2 (en) * | 2011-09-28 | 2018-06-05 | Idemitsu Korea Co., Ltd. | Material for organic electroluminescent element, and organic electroluminescent element produced using same |
| RS61033B1 (sr) | 2011-11-28 | 2020-12-31 | Merck Patent Gmbh | Antitela na pd-l1 i njihova upotreba |
| US10023643B2 (en) | 2011-12-15 | 2018-07-17 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R and uses thereof |
| BR112014018961A8 (pt) | 2012-02-06 | 2017-07-11 | Genentech Inc | Anticorpo isolado, anticorpo biespecífico, fragmento, ácido nucleico isolado, vetor, célula hospedeira, método de produção de anticorpos, composição farmacêutica, uso do anticorpo, método de tratamento, método de inibição e artigo industrializado |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| BR112014028013A2 (pt) | 2012-05-11 | 2018-02-27 | Five Prime Therapeutics Inc | métodos para tratar uma condição associada com artrite reumatoide, artrite reumatoide, lesões de pele, nefrite lúpica, lúpus, uma condição inflamatória, distúrbio de cd16+, método para reduzir o número de monócitos cd16+, métodos para desacelerar a progressão de uma condição renal,de formação de panos e de perda óssea |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| UA115576C2 (uk) * | 2012-12-06 | 2017-11-27 | Байєр Фарма Акцієнгезелльшафт | Похідні бензимідазолу як антагоністи ер4 |
| WO2014134267A1 (en) * | 2013-02-27 | 2014-09-04 | Bristol-Myers Squibb Company | Carbazole compounds useful as bromodomain inhibitors |
| US9492460B2 (en) | 2013-02-27 | 2016-11-15 | Bristol-Myers Squibb Company | Carbazole compounds useful as bromodomain inhibitors |
| WO2014164596A1 (en) * | 2013-03-11 | 2014-10-09 | The Regents Of The University Of Michigan | Bet bromodomain inhibitors and therapeutic methods using the same |
| PL3466949T3 (pl) * | 2013-12-24 | 2021-05-31 | Bristol-Myers Squibb Company | Związek tricykliczny jako środki przeciwrakowe |
-
2014
- 2014-12-23 PL PL18192207T patent/PL3466949T3/pl unknown
- 2014-12-23 LT LTEP14824743.0T patent/LT3087071T/lt unknown
- 2014-12-23 ES ES14824743T patent/ES2698998T3/es active Active
- 2014-12-23 PT PT181922071T patent/PT3466949T/pt unknown
- 2014-12-23 PE PE2016000945A patent/PE20160844A1/es unknown
- 2014-12-23 ES ES18192207T patent/ES2857848T3/es active Active
- 2014-12-23 LT LTEP18192207.1T patent/LT3466949T/lt unknown
- 2014-12-23 RS RS20210158A patent/RS61479B1/sr unknown
- 2014-12-23 SM SM20180643T patent/SMT201800643T1/it unknown
- 2014-12-23 JP JP2016542692A patent/JP6466456B2/ja active Active
- 2014-12-23 SM SM20210165T patent/SMT202100165T1/it unknown
- 2014-12-23 SG SG11201605097SA patent/SG11201605097SA/en unknown
- 2014-12-23 MX MX2016007928A patent/MX369491B/es active IP Right Grant
- 2014-12-23 AU AU2014369982A patent/AU2014369982B2/en active Active
- 2014-12-23 HU HUE18192207A patent/HUE054183T2/hu unknown
- 2014-12-23 DK DK18192207.1T patent/DK3466949T3/da active
- 2014-12-23 SI SI201431748T patent/SI3466949T1/sl unknown
- 2014-12-23 UY UY0001035916A patent/UY35916A/es unknown
- 2014-12-23 DK DK14824743.0T patent/DK3087071T3/da active
- 2014-12-23 NZ NZ72232614A patent/NZ722326A/en not_active IP Right Cessation
- 2014-12-23 AR ARP140104912A patent/AR099379A1/es active IP Right Grant
- 2014-12-23 EA EA201990240A patent/EA201990240A1/ru unknown
- 2014-12-23 TW TW103145061A patent/TWI736517B/zh active
- 2014-12-23 EA EA201691070A patent/EA032469B1/ru not_active IP Right Cessation
- 2014-12-23 CN CN201810460901.7A patent/CN108558871B/zh active Active
- 2014-12-23 SI SI201430891T patent/SI3087071T1/sl unknown
- 2014-12-23 TN TN2016000238A patent/TN2016000238A1/en unknown
- 2014-12-23 BR BR112016013744-2A patent/BR112016013744B1/pt active IP Right Grant
- 2014-12-23 CA CA2934953A patent/CA2934953C/en active Active
- 2014-12-23 CN CN201480076189.0A patent/CN106029663B/zh active Active
- 2014-12-23 PT PT14824743T patent/PT3087071T/pt unknown
- 2014-12-23 US US15/107,652 patent/US20160318928A1/en not_active Abandoned
- 2014-12-23 MA MA39211A patent/MA39211B1/fr unknown
- 2014-12-23 HR HRP20181849TT patent/HRP20181849T1/hr unknown
- 2014-12-23 WO PCT/US2014/072031 patent/WO2015100282A1/en not_active Ceased
- 2014-12-23 PL PL14824743T patent/PL3087071T3/pl unknown
- 2014-12-23 EP EP14824743.0A patent/EP3087071B1/en active Active
- 2014-12-23 TW TW108146502A patent/TWI726544B/zh active
- 2014-12-23 KR KR1020167019782A patent/KR102457145B1/ko active Active
- 2014-12-23 MY MYPI2016702341A patent/MY176489A/en unknown
- 2014-12-23 RS RS20181319A patent/RS58014B1/sr unknown
- 2014-12-23 EP EP18192207.1A patent/EP3466949B1/en active Active
- 2014-12-23 HU HUE14824743A patent/HUE041719T2/hu unknown
-
2016
- 2016-05-24 PH PH12016500953A patent/PH12016500953A1/en unknown
- 2016-06-20 IL IL246359A patent/IL246359B/en active IP Right Grant
- 2016-06-23 CL CL2016001629A patent/CL2016001629A1/es unknown
-
2018
- 2018-12-04 CY CY181101293T patent/CY1121076T1/el unknown
-
2019
- 2019-01-09 JP JP2019002078A patent/JP6675501B2/ja active Active
-
2021
- 2021-02-08 HR HRP20210212TT patent/HRP20210212T8/hr unknown
- 2021-03-17 CY CY20211100226T patent/CY1124061T1/el unknown
- 2021-11-03 AR ARP210103062A patent/AR123996A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ722326A (en) | Tricyclic compounds as anticancer agents | |
| MY196319A (en) | Polycyclic TLR7/8 Antagonists and use Thereof in the Treatment of Immune Disorders | |
| MX2015010921A (es) | Compuestos de carbazol utiles como inhibidores de bromodominio. | |
| MY201925A (en) | Macrocyclic compounds and uses thereof | |
| MX2016002544A (es) | Compuestos utiles como inmunomoduladores. | |
| MX2019001125A (es) | Inhibidores de cinasa macrociclica. | |
| MX2015014181A (es) | 2-acetilnafto [2,3-b]furano -4,9-diona para uso en el tratamiento del cáncer. | |
| MX2015011898A (es) | Compuestos de pirazolo y usos de los mismos. | |
| MX2015014947A (es) | 5-(3,5-dimetilisoxazol-4-il)indolina-2-onas sustituidas. | |
| WO2014152029A3 (en) | Oxazolo[5,4-c]quinolin-2-one compounds as bromodomain inhibitors | |
| SG10201808102WA (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| MX2015012502A (es) | Inhibidores de proteina cinasa dependiente de adn. | |
| SG10201804868PA (en) | Compounds for the inhibition of indoleamine-2,3-dioxygenase | |
| WO2014194254A8 (en) | Treatment of cancers using pi3 kinase isoform modulators | |
| MX2015014234A (es) | Derivados 2-aminopirido-[4,3-d]pirimidin-5-ona y su uso como inhibidores de wee-1. | |
| MY181602A (en) | Isochromene derivatives as phosphoinositide 3-kinases inhibitors | |
| MX2022001310A (es) | Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo. | |
| SG10201805267UA (en) | Piperazine derivatives having multimodal activity against pain | |
| SG10201810660QA (en) | Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain | |
| MX2017006437A (es) | Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor. | |
| AU2018253600A1 (en) | Dosage forms and therapeutic uses of l-4-chlorokynurenine | |
| MX376090B (es) | Derivados de cromeno como inhibidores de las fosfoinositido-3-cinasas. | |
| MX2017006513A (es) | Compuestos de tipo 1,9-diazaespiroundecano con actividad multimodal contra el dolor. | |
| IN2013MU03118A (OSRAM) | ||
| MY182818A (en) | Compositions for the treatment of fibrosis and fibrosis-related conditions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 DEC 2021 BY CPA GLOBAL Effective date: 20201105 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 DEC 2022 BY CPA GLOBAL Effective date: 20211111 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 DEC 2023 BY CPA GLOBAL Effective date: 20221111 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 DEC 2024 BY CPA GLOBAL Effective date: 20231109 |
|
| LAPS | Patent lapsed |